Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies

Area of Science:

• Immunology
• Rheumatology
• Pathology

Background:

• Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease impacting synovial joints.
• RA leads to progressive disability, premature mortality, and significant socioeconomic burdens.
• Current treatments, including disease-modifying anti-rheumatic drugs (DMARDs), are insufficient for a substantial patient subset.

Purpose of the Study:

• To dissect the etiology and pathology of rheumatoid arthritis (RA) across distinct disease stages.
• To review recent advancements in understanding RA pathogenesis and current therapeutic strategies.
• To provide perspectives on next-generation therapeutics for RA.

Main Methods:

• Review of current literature on rheumatoid arthritis (RA) pathogenesis.
• Analysis of disease progression through defined stages: triggering, maturation, targeting, and fulminant.
• Examination of pathological hallmarks including synovial hyperplasia, cartilage damage, and bone erosion.

Main Results:

• RA progression involves distinct pathological stages with specific clinical manifestations.
• Despite advances in pharmacologic therapies (conventional, biological, small molecule DMARDs), many RA patients exhibit inadequate responses.
• Significant unmet needs exist for novel therapeutics to address non-responsive RA cases.

Conclusions:

• A comprehensive understanding of RA pathogenesis across its stages is crucial for targeted therapy development.
• Novel therapeutic approaches are urgently needed to improve outcomes for RA patients who do not respond to existing treatments.
• Future research should focus on next-generation therapeutics to achieve disease remission and prevent joint deformity in RA.